The utilization of SGLT2 inhibitors has been proposed to lower cardiovascular risk in individuals diagnosed with T2DM by effectively decreasing hyperglycemia, BP, and body weight. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.